The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 119:61-67, July 1962
doi: 10.1176/appi.ajp.119.1.61
© 1962 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by LUBY, E. D.
* Articles by DOMINO, E. F.
* Search for Related Content
PubMed
* Articles by LUBY, E. D.
* Articles by DOMINO, E. F.

MODEL PSYCHOSES AND SCHIZOPHRENIA

ELLIOT D. LUBY M.D., JACQUES S. GOTTLIEB M.D., BERTRAM D. COHEN PH.D., GERALD ROSENBAUM PH.D., , and EDWARD F. DOMINO M.D.1

1 The Lafayette Clinic and Wayne State University, Detroit, Mich.

All model psychoses may be conceptualized as resulting from disruption in the central processing or from interference with the normal sensory influx from body or distance receptors. The experimental findings of the effects of sleep deprivation, sensory isolation, drugs, and a combination of drugs and sensory isolation in control and schizophrenic subjects warrants the development of a hypothesis within this context to explain some of the mechanisms responsible for schizophrenic behavior. Such a hypothesis must be operational in the sense that its elements must be susceptible to experimental verification.

Evidence has been presented that sleep deprivation is at first accompanied by an adaptive high biologic energy turnover, but that finally a point is reached after several days when energy producing mechanisms decompensate. Moreover, it appears possible that a "stressor substance" develops in the serum of these subjects which may be responsible for the progressive failure of the mechanism of energy turnover.

While the failure in the mechanism of adaptation for supplying the needed biologic energy for sleep-deprived subjects is reversible, one may ponder about its relationship to the permanently disturbed mechanisms controlling the formation and utilization of biologic energy that characterizes the chronic schizophrenic patient. Two questions are pertinent. Do traumatic sociopsychological experiences at an early period of life when these biochemical mechanisms are in the process of maturation limit their adaptive responsivity ? Conversely, does inadequate exposure to normal sociopsychologic stressors at a critical maturational period inhibit their development?

How does the succinic oxidase inhibiting "stressor" substance in the serum of persons deprived of sleep relate to the alpha globulin in the serum of schizophrenic patients, which shifts intermediary carbohydrate metabolism to more anaerobic mechanisms? Only further study will tell, but it is conceivable that they are related.

Nevertheless, the alpha globulin isolated by Frohman and others from the plasma of schizophrenic patients apparently affects neutral transmission centrally. It alters the behavior of monkeys and rats and according to Marrazzi inhibits transcallosal synaptic conduction(27, 28). This need not necessarily imply ease of passage through blood brain barrier because the protein may act by increasing permeability or as a carrier system for a smaller molecule. Our studies on model psychoses can, perhaps, contribute to a hypothesis concerning the mechanism of action of this substance.

Meaningful exteroceptive input is necessary for normal psychological functioning, but apparently induces aversive responses in schizophrenic patients. This suggests that the central stimulus filtering and interpretation capacity of these patients is diminished. Conceivably the defect may be similar to that produced by Sernyl and involve the disruption or reduction of body input transmission and integration.

In Kubie's parlance, when the subject's image of himself, "the I," is destroyed, the ability to assess external reality or the "not I" is lost(29). As Federn suggested, depersonalization may be the core of schizophrenia (30), and disturbed body input transmission or integration may be its basis. In our hypothesis such disturbed neural integration in schizophrenia might result either from the presence of an inhibitor substance or from a defect in energy production.

Analogous situations in the animal can be produced by psychotomimetic drugs such as Sernyl or by lesions in lateral midbrain involving tracts mediating touch, proprioception, and pain. Sernyl has been shown by Lees to be an uncoupling agent (31). It may thus reduce available energy stores, although admittedly other uncoupling drugs do not produce psychotomimetic effects. That Sernyl has profound action on central reception and integration of body input is evidenced by the work of Van Meter, et al.(32), and Domino(26). At the cortical level both axosomatic and axodendritic synapses are partially blocked by the drug. There is also evidence for depression of the diffuse thalamic projection system.

Recent work on destruction of lemniscal pathways in the cat by Sprague, Chambers, and Stellar might lend additional support to our hypothesis. When the sensory afferent systems mediating proprioception, pain, and touch in these animals were cut, severe behavioral changes occurred. The cat was rendered incapable of attending to or making adaptive responses to relevant stimuli associated with eating, sexuality, or defense. Emotionality was diminished and the cats seemed flat and automaton-like. At times they appeared to be hallucinating(33).

These disrupted body input mechanist may be considered as responsible for the disturbances in psychological functioning of the schizophrenic patient. This aspect of our hypothesis could be easily subjected to direct test if the human brain were readily available for experimentation and study. Being realistic, however, we must have recourse to analogous study in animals to increase our knowledge. This prolongs and complicates the challenge.




This article has been cited by other articles:


Home page
Br. J. PsychiatryHome page
E. Pomarol-Clotet, G. D. Honey, G. K. Murray, P. R. Corlett, A. R. Absalom, M. Lee, P. J. McKenna, E. T. Bullmore, and P. C. Fletcher
Psychological effects of ketamine in healthy volunteers: Phenomenological study
The British Journal of Psychiatry, August 1, 2006; 189(2): 173 - 179.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
N. Pillai-Nair, A. K. Panicker, R. M. Rodriguiz, K. L. Gilmore, G. P. Demyanenko, J. Z. Huang, W. C. Wetsel, and P. F. Maness
Neural Cell Adhesion Molecule-Secreting Transgenic Mice Display Abnormalities in GABAergic Interneurons and Alterations in Behavior
J. Neurosci., May 4, 2005; 25(18): 4659 - 4671.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
R. E. Smith, V. Haroutunian, K. L. Davis, and J. H. Meador-Woodruff
Expression of Excitatory Amino Acid Transporter Transcripts in the Thalamus of Subjects With Schizophrenia
Am J Psychiatry, September 1, 2001; 158(9): 1393 - 1399.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
H. M. Ibrahim, A. J. Hogg Jr., D. J. Healy, V. Haroutunian, K. L. Davis, and J. H. Meador-Woodruff
Ionotropic Glutamate Receptor Binding and Subunit mRNA Expression in Thalamic Nuclei in Schizophrenia
Am J Psychiatry, November 1, 2000; 157(11): 1811 - 1823.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
J. D. Jentsch, J. D. Elsworth, D. E. Redmond Jr., and R. H. Roth
Phencyclidine Increases Forebrain Monoamine Metabolism in Rats and Monkeys: Modulation by the Isomers of HA966
J. Neurosci., March 1, 1997; 17(5): 1769 - 1775.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1962 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org